Applying trained immunity therapy in NASH-HCC patients may initially encounter greater resistance, as trained monocytes could be rapidly deactivated by elevated IL-10 and fatty acids in NASH livers, while trained neutrophils might revert under NASH-associated cytokines. The gene discussed is IL10; the disease is metabolic dysfunction-associated steatohepatitis.